

From the hope to the ontarget and the transcend studie
prognosis

American Journal of Cardiology

89, 18-25

DOI: 10.1016/s0002-9149(01)02323-2

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comparative Effects of Telmisartan in the Treatment of Hypertension. Journal of Clinical Hypertension, 2000, 5, 20-25.	1.0	2
2	Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. Journal of Clinical Hypertension, 2000, 5, 26-31.	1.0	11
3	Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 66-71.	1.0	6
4	Vascular and cardiac benefits of angiotensin receptor blockers. American Journal of Medicine, 2002, 113, 409-418.	0.6	119
5	The vulnerable plaque and acute coronary syndromes. American Journal of Medicine, 2002, 113, 668-680.	0.6	94
6	Treatment of hypertension with an angiotensin II receptor antagonist compared with an angiotensin-converting enzyme inhibitor: A review of clinical studies of telmisartan and enalapril. Clinical Therapeutics, 2002, 24, 1484-1501.	1.1	41
7	Tratamiento de la hipertensi3n arterial con antagonistas de los receptores de la angiotensina II. Hipertension Y Riesgo Vascular, 2002, 19, 257-261.	0.3	0
8	Angiotensin II and trials of cardiovascular outcomes11Reprints are not available.. American Journal of Cardiology, 2002, 89, 11-16.	0.7	62
9	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Current Atherosclerosis Reports, 2002, 4, 363-372.	2.0	33
10	Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Current Hypertension Reports, 2003, 5, 129-134.	1.5	48
11	Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 312-317.	1.4	15
12	Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportion. American Journal of Cardiology, 2003, 92, 1439-1441.	0.7	58
13	Actualizaci3n (2003) de las GuÃas de PrÃctica ClÃnica de la Sociedad EspaÃola de CardiologÃa en hipertensi3n arterial. Revista Espanola De Cardiologia, 2003, 56, 487-497.	0.6	37
14	Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function. Blood Pressure, 2003, 12, 70-88.	0.7	382
15	Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice. Journal of Clinical Hypertension, 2003, 5, 414-420.	1.0	20
16	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	13.9	2,240
18	Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. International Journal of Biochemistry and Cell Biology, 2003, 35, 826-837.	1.2	98
19	Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders. American Journal of Cardiovascular Drugs, 2003, 3, 389-394.	1.0	64

#	ARTICLE	IF	CITATIONS
20	Review: Potential of renin inhibition in cardiovascular disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 6-10.	1.0	65
21	Drug Therapy and Heart Failure Prevention. Circulation, 2003, 107, 1234-1236.	1.6	18
22	Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2003, 4, 62-73.	1.0	9
23	End-organ damage: does it really matter how we prevent it?. European Heart Journal Supplements, 2003, 5, F33-F39.	0.0	0
24	PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme. European Heart Journal Supplements, 2003, 5, F40-F47.	0.0	1
25	Renin-Angiotensin System and Atherothrombotic Disease. Archives of Internal Medicine, 2003, 163, 1155.	4.3	108
26	New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. Journal of Hypertension, 2003, 21, 1599-1608.	0.3	33
27	Heart failure and the brain: new perspectives. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2003, 284, R259-R276.	0.9	110
28	Angiotensin II, PPAR-Gamma and atherosclerosis. Frontiers in Bioscience - Landmark, 2004, 9, 359.	3.0	31
29	Practical Efficacy of Telmisartan for Decreasing Morning Home Blood Pressure and Pulse Wave Velocity in Patients with Mild-to-Moderate Hypertension. Hypertension Research, 2004, 27, 545-550.	1.5	38
30	Antihypertensive Therapy and Incidence of Type 2 Diabetes in an Elderly Cohort. Diabetes Care, 2004, 27, 2458-2463.	4.3	51
31	Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist. Journal of the American Society of Nephrology: JASN, 2004, 15, 71S-76.	3.0	30
32	New Perspectives on the Pharmacotherapy of Ischemic Stroke. Journal of the American Pharmacists Association: JAPhA, 2004, 44, S46-S56.	0.7	12
33	Angiotensin II, platelets and oxidative stress. Journal of Hypertension, 2004, 22, 1085-1086.	0.3	11
34	Diabetic renal disease: from recent studies to improved clinical practice. Diabetic Medicine, 2004, 21, 4-17.	1.2	45
35	The Role of Angiotensin Receptor Blockers and/or Angiotensin Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases:. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1405-1410.	0.5	90
37	Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Current Hypertension Reports, 2004, 6, 369-376.	1.5	12
38	Coronary artery disease and prevention of heart failure. Medical Clinics of North America, 2004, 88, 1209-1235.	1.1	23

#	ARTICLE	IF	CITATIONS
39	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	0.6	8
40	Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System. Drugs, 2004, 64, 2537-2565.	4.9	239
41	Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review. Diabetes Care, 2004, 27, 247-255.	4.3	185
42	Genetic Determinants of Arterial Calcification Associated With Atherosclerosis. Mayo Clinic Proceedings, 2004, 79, 197-210.	1.4	46
43	Antihypertensive medications for risk reduction of first and recurrent ischemic stroke. Expert Review of Cardiovascular Therapy, 2004, 2, 867-876.	0.6	2
44	Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. American Heart Journal, 2004, 148, 747-754.	1.2	64
45	The American Heart Association get with the guidelines program. American Heart Journal, 2004, 148, S46-S48.	1.2	244
46	Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. Journal of Clinical Hypertension, 2004, 6, 445-451.	1.0	14
48	Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. European Journal of Clinical Pharmacology, 2004, 59, 863-868.	0.8	106
49	Renin???angiotensin system blockade. Journal of Hypertension, 2004, 22, 459-462.	0.3	1
50	Genetic determinants of blood pressure regulation. Journal of Hypertension, 2005, 23, 2127-2143.	0.3	94
51	Why blockade of the renin?angiotensin system reduces the incidence of new-onset diabetes. Journal of Hypertension, 2005, 23, 463-473.	0.3	259
52	Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. Journal of Human Hypertension, 2005, 19, 173-183.	1.0	24
53	Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. Journal of Human Hypertension, 2005, 19, 923-931.	1.0	51
54	Effect of losartan on muscle sympathetic activity and baroreceptor function in systemic hypertension. American Journal of Cardiology, 2005, 95, 129-131.	0.7	18
55	Comparison of the Effects of Ramipril Versus Telmisartan in Reducing Serum Levels of High-Sensitivity C-Reactive Protein and Oxidized Low-Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2005, 95, 1386-1388.	0.7	58
56	Interrelationships Between the Autonomic Nervous System and Atrial Fibrillation. Progress in Cardiovascular Diseases, 2005, 48, 57-78.	1.6	80
57	Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions. Pharmacotherapy, 2005, 25, 1213-1229.	1.2	83

#	ARTICLE	IF	CITATIONS
58	Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?. <i>Current Hypertension Reports</i> , 2005, 7, 44-51.	1.5	17
59	Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice. <i>Current Hypertension Reports</i> , 2005, 7, 314-322.	1.5	22
60	Management of patients with type 2 diabetes after acute coronary syndromes. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, 144-154.	0.9	7
61	A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 736-744.	4.3	150
62	The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. <i>Cardiology Clinics</i> , 2005, 23, 165-183.	0.9	23
63	Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers. <i>American Journal of Hypertension</i> , 2005, 18, 720-730.	1.0	105
64	The Role of Oral Antiplatelet Agents in Atherothrombotic Disease. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 149-157.	1.0	16
65	Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2006, 81, 796-806.	1.4	61
67	A Multicenter, 14-Week Study of Telmisartan and Ramipril in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. <i>American Journal of Hypertension</i> , 2006, 19, 104-112.	1.0	54
68	Renin inhibition. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 505-510.	1.0	21
69	Synthesis of Biaryls via Catalytic Decarboxylative Coupling. <i>Science</i> , 2006, 313, 662-664.	6.0	872
70	Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillationâ€™ indications and contraindications. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 220-225.	3.3	17
71	Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 1-15.	1.0	31
72	Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, S1.	1.0	24
73	Blood pressure control and prevention of stroke. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 203-212.	1.4	0
74	Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. <i>Journal of Human Hypertension</i> , 2007, 21, 699-708.	1.0	6
75	Effects of Bradykinin on Aortic Endothelial Function in ApoE-Knockout Mice With Chronic Chlamydia Pneumoniae Infection. <i>Circulation Journal</i> , 2007, 71, 1480-1484.	0.7	6
76	Combination ACE Inhibitor and Angiotensin Receptor Blocker Therapyâ€™Future Considerations. <i>Journal of Clinical Hypertension</i> , 2007, 9, 78-86.	1.0	12

#	ARTICLE	IF	CITATIONS
77	An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. <i>Life Sciences</i> , 2007, 81, 615-639.	2.0	64
78	Renin: friend or foe?. <i>Heart</i> , 2007, 93, 1026-1033.	1.2	74
79	Biaryl Synthesis via Pd-Catalyzed Decarboxylative Coupling of Aromatic Carboxylates with Aryl Halides. <i>Journal of the American Chemical Society</i> , 2007, 129, 4824-4833.	6.6	437
80	Coronary Heart Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 631-642.	1.2	132
81	Hypertension and Diabetes Mellitus. , 2007, , 406-417.		4
82	The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 617-629.	2.2	10
83	Prevention of Stroke in Patients with Hypertension. <i>American Journal of Cardiology</i> , 2007, 100, S17-S24.	0.7	59
84	Blood Pressure Lowering Only or More? Has the Jury Reached Its Verdict?. <i>American Journal of Cardiology</i> , 2007, 100, S32-S37.	0.7	6
85	Direct renin inhibition: clinical pharmacology. <i>Journal of Molecular Medicine</i> , 2008, 86, 647-654.	1.7	18
86	The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. <i>International Journal of Clinical Practice</i> , 2008, 62, 1397-1402.	0.8	20
87	RENIN INHIBITION WITH ALISKIREN. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 426-430.	0.9	15
88	Implicaciones del estudio ONTARGET en hipertensi3n arterial y diabetes tipo 2. <i>Revista Espanola De Cardiologia Suplementos</i> , 2008, 8, 56E-62E.	0.2	0
89	Possible mechanisms and controversies of protective effects of risk factors against stroke severity. <i>Journal of the Neurological Sciences</i> , 2008, 267, 188-189.	0.3	4
90	Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 239-266.	2.3	20
91	Risk Factor Management to Prevent First Stroke. <i>Neurologic Clinics</i> , 2008, 26, 1007-1045.	0.8	48
92	Telmisartan as a metabolic sartan for targeting vascular failure. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1397-1406.	0.9	13
93	Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 935-940.	0.5	16
94	Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. <i>American Journal of Hypertension</i> , 2008, 21, 248-256.	1.0	14

#	ARTICLE	IF	CITATIONS
95	Transition-Metal-Catalyzed Direct Arylation of (Hetero)Arenes by C-H Bond Cleavage. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 9792-9826.	7.2	2,623
96	Silica-supported palladium: Sustainable catalysts for cross-coupling reactions. <i>Coordination Chemistry Reviews</i> , 2009, 253, 2599-2626.	9.5	476
97	Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 29-43.	1.0	16
98	Preventing stroke: the PROFESS, ONTARGET, and TRANSCEND trial programs. <i>Journal of Hypertension</i> , 2009, 27, S31-S36.	0.3	23
100	Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. <i>Internal and Emergency Medicine</i> , 2010, 5, 469-479.	1.0	14
101	ACE Inhibition Reduces Infarction in Normotensive but Not Hypertensive Rats: Correlation with Cortical ACE Activity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1520-1526.	2.4	21
102	Antiatherogenic properties of flavonoids: Implications for cardiovascular health. <i>Canadian Journal of Cardiology</i> , 2010, 26, 17A-21A.	0.8	154
104	Synthesis of Biaryls via AlCl ₃ Catalyzed Domino Reaction Involving Cyclization, Dehydration, and Oxidation. <i>Organic Letters</i> , 2011, 13, 6140-6143.	2.4	27
105	Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2011, 100, 603-610.	1.5	32
106	Nanocrystalline Titania-Supported Palladium(0) Nanoparticles for Suzuki-Miyaura Cross-Coupling of Aryl and Heteroaryl Halides. <i>Advanced Synthesis and Catalysis</i> , 2011, 353, 2823-2836.	2.1	47
107	Direct Renin Inhibition. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 93-105.	1.0	18
108	Organometallics aspects of C-H bond activation/functionalization. <i>Organometallic Chemistry</i> , 2012, , 48-74.	0.6	4
109	Heart Failure in Hypertension. <i>Drugs</i> , 2012, 72, 1373-1398.	4.9	16
110	Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. <i>Journal of Cardiology</i> , 2012, 59, 91-96.	0.8	7
111	Solid-Phase Organic Synthesis and Catalysis: Some Recent Strategies Using Alumina, Silica, and Polyionic Resins. <i>Journal of Catalysts</i> , 2013, 2013, 1-20.	0.5	12
112	Organometallic aspects of transition-metal catalysed regioselective C-H bond functionalisation of arenes and heteroarenes. <i>Dalton Transactions</i> , 2014, 43, 3021.	1.6	37
113	Synthesis of substituted indolizines via radical oxidative decarboxylative annulation of 2-(pyridin-2-yl)acetate derivatives with 1,2-unsaturated carboxylic acids. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 9966-9969.	1.5	11
114	Bio-Waste Corn-cob Cellulose Supported Poly(amidoxime) Palladium Nanoparticles for Suzuki-Miyaura Cross-Coupling Reactions. <i>ChemistrySelect</i> , 2016, 1, 4108-4112.	0.7	17

#	ARTICLE	IF	CITATIONS
115	Synthesis of Highly Substituted Biaryls by the Construction of a Benzene Ring via In Situ Formed Acetals. <i>Journal of Organic Chemistry</i> , 2021, 86, 11871-11883.	1.7	4
117	AT1 Receptor Antagonists: Pharmacology. <i>Handbook of Experimental Pharmacology</i> , 2004, , 417-451.	0.9	3
118	Can Angiotensin-converting Enzyme Inhibitors Reverse Atherosclerosis?. <i>Southern Medical Journal</i> , 2003, 96, 569-579.	0.3	9
119	Stimulation of AT2 receptors. , 2006, , 31-46.		1
120	Valsartan in the treatment of heart attack survivors. <i>Vascular Health and Risk Management</i> , 2006, 2, 125-138.	1.0	25
121	Inhibitors of the RAS: Evidence-Based Medicine. <i>Handbook of Experimental Pharmacology</i> , 2004, , 545-592.	0.9	0
122	Clinical Pharmacology of Angiotensin II Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2004, , 453-484.	0.9	0
123	Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2004, , 485-516.	0.9	0
124	Angiotensin II and Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2004, , 21-38.	0.9	1
125	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2004, , 179-206.		0
126	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2008, , 201-229.		0
128	Hemmstoffe des Renin-Angiotensin-Systems. , 2009, , 203-235.		0
129	Hemmstoffe des Renin-Angiotensin-Systems. , 2010, , 219-252.		0
130	Hemmstoffe des Renin-Angiotensin-Systems. , 2011, , 225-260.		0
131	Hemmstoffe des Renin-Angiotensin-Systems. , 2012, , 225-262.		0
132	Hemmstoffe des Renin-Angiotensin-Systems. , 2013, , 217-256.		0
133	Hemmstoffe des Renin-Angiotensin-Systems. , 2016, , 209-235.		0
134	Hemmstoffe des Renin-Angiotensin-Systems. , 2017, , 211-236.		0

#	ARTICLE	IF	CITATIONS
135	Hemmstoffe des Renin-Angiotensin-Systems. , 2018, , 263-288.		0
136	Hemmstoffe des Renin-Angiotensin-Systems. , 2019, , 359-388.		0
137	Hemmstoffe des Renin-Angiotensin-Systems. , 2020, , 231-259.		0
138	Role of Angiotensin-Receptor Blockers in the Prevention of Cardiovascular Risk: Clinical Guidelines. , 2007, , 425-432.		0
140	Diabetic Renal and Related Heart Disease. , 2006, , 437-451.		0
143	Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center. MedGenMed: Medscape General Medicine, 2007, 9, 40.	0.2	0
144	Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vascular Health and Risk Management, 2007, 3, 937-45.	1.0	22
145	Hemmstoffe des Renin-Angiotensin-Systems. , 2021, , 131-161.		0
146	Comparative effects of telmisartan in the treatment of hypertension. Journal of Clinical Hypertension, 2002, 4, 20-5.	1.0	2